PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1682818
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1682818
The non-invasive prenatal testing (NIPT) market is experiencing significant growth, driven by the increasing prevalence of chromosomal abnormalities and the rising demand for early detection methods. In 2024, the market size is estimated at USD 7.1 billion and is projected to reach USD 21.2 billion by 2032, advancing at a compound annual growth rate (CAGR) of 14.7% during the forecast period.
This growth is primarily attributed to the increasing prevalence of chromosomal abnormalities and rising demand for early detection methods. Approximately 14% of stillbirths are due to inherited diseases in pregnant women under 24 years old, with the number rising to 38% in women aged 40-44.
Key Insights
NIPT is predominantly used for detecting trisomies, with Trisomy 21 (Down syndrome) being the most common chromosomal abnormality. In the U.S., more than 5,000 babies are born with Down syndrome annually, equating to an incidence of 1 in 800 newborns. The likelihood of Down syndrome increases with maternal age, and infants born with this condition often have low birth weights, with approximately 85% dying within a year and only 50% living longer than 50 years.
The adoption of advanced technologies, such as next-generation sequencing (NGS), has enhanced the accuracy and efficiency of NIPT. NGS facilitates the detection of chromosomal abnormalities by analyzing fetal DNA present in maternal blood, leading to early and reliable diagnoses.
Diagnostic laboratories are the primary end-users of NIPT, owing to their specialized equipment and expertise in genetic testing. Hospitals and research institutes also utilize NIPT, reflecting its integration into prenatal care and ongoing genetic research.
North America holds the largest market share, attributed to the high adoption rate of advanced diagnostic technologies and well-established healthcare infrastructure. The Asia-Pacific region is anticipated to witness the fastest growth, driven by increasing healthcare awareness, rising disposable incomes, and expanding access to prenatal care services.
The NIPT market is fragmented, with numerous players offering a variety of products to cater to diverse consumer needs. Major companies in the market include Illumina Inc., Eurofins Scientific SE, Myriad Women's Health Inc., PerkinElmer Inc., Agilent Technologies Inc., QIAGEN N.V., Danaher Corporation, Bio-Rad Laboratories Inc., Laboratory Corp. of America Holdings, Quest Diagnostics Inc., Yourgene Health plc, and Thermo Fisher Scientific Inc.